Wednesday, December 29, 2010
Merck confirms plans for developing vernakalant drug for atrial fibrillation
Cardiome Pharma Corp. today announced that it has been advised by its partner, Merck, that the current review of vernakalant is complete, and that Merck has informed Cardiome of its next steps in clinical development for vernakalant beginning in 2011.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment